ad image

Company Info

Vertex

Vertex

Drug Discovery & Development

Overview

Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has three approved medicines that treat the underlying cause of cystic fibrosis (CF) - a rare, life-threatening genetic disease - and has several ongoing clinical and research programs in CF. Beyond CF, Vertex has a robust pipeline of investigational medicines in other serious diseases where it has deep insight into causal human biology, such as sickle cell disease, beta thalassemia, pain, alpha-1 antitrypsin deficiency, Duchenne muscular dystrophy and APOL1-mediated kidney diseases.
Vertex
Contributions
8 Contributions1 / 1
Vertex
Collaboration

Vertex and Obsidian Therapeutics Establish Collaboration to Discover Novel Therapies That Regulate Gene Editing

Vertex

PR-M04-21-024Apr 22, 2021
Vertex
Gene Editing

Vertex Announces New Clinical Data for Investigational Gene-Editing Therapy CTX001™ in Severe Hemoglobinopathies

Vertex

PR-M06-20-NI-017Jun 12, 2020
Vertex
Cell and Gene Therapy

CRISPR Therapeutics and Vertex Announce Positive Safety and Efficacy Data From First Two Patients Treated With Investigational CRISPR/Cas9 Gene-Editing Therapy CTX001® for Severe Hemoglobinopathies

Vertex

PR-M11-19-NI-023Nov 20, 2019
Vertex
Agreement

Vertex Announces New Access Agreement with Scottish Government for ORKAMBI® (lumacaftor/ivacaftor) and SYMKEVI® (tezacaftor/ivacaftor)

Vertex

PR-M09-19-NI-041Sep 16, 2019
Vertex
M&A

Vertex to Acquire Semma Therapeutics With a Goal of Developing Curative Cell-Based Treatments for Type 1 Diabetes

Vertex

PR-M09-19-NI-008Sep 04, 2019
Vertex
Leadership

Vertex Announces Dr. Jeffrey Leiden to Transition to Role of Executive Chairman and Dr. Reshma Kewalramani Appointed as New CEO

Vertex

PR-M07-19-NI-076Jul 29, 2019
Vertex
FDA Approval

FDA Approves KALYDECO® (ivacaftor) as First and Only Medicine to Treat the Underlying Cause of CF in Children Ages 12 to <24 Months with Certain Mutations in the CFTR Gene

Vertex

PR-M09-18-NI-050Sep 19, 2018
Vertex
FDA Approval

FDA Approves ORKAMBI® (lumacaftor/ivacaftor) as First Medicine to Treat the Underlying Cause of Cystic Fibrosis for Children Ages 2-5 Years with Most Common Form of the Disease

Vertex

PR-M08-18-NI-075Aug 20, 2018
1 / 1
0 Contributors1 / 0

No authors found

1 / 0